Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI8968
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
MEDI8968 is a fully human monoclonal antibody that targets the interleukin-1 receptor type 1 (IL-1R1). Developed by AstraZeneca through its MedImmune subsidiary, the drug was designed to block the signaling of interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), cytokines that play a central role in the inflammatory response. It was primarily evaluated for the treatment of moderate to severe hidradenitis suppurativa (HS) and chronic obstructive pulmonary disease (COPD). In a Phase IIa study for HS, MEDI8968 failed to show a statistically significant improvement in clinical response compared to placebo, leading to the cessation of development for this indication.
- Other names
- anti-IL-1R1 antibodyanti-IL1R1 antibodyanti-IL 1R1 antibody
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on MEDI8968.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI8968.